Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJane ShinglesNWNichola WebsterARAndy C. Rawstron

Discussion

Loading...

Member takes

Overview

Phase III trial shows MRD-guided ibrutinib and venetoclax improves progression-free survival in CLL patients with TP53 aberrations, indicating efficacy over standard treatments.

Key Points

  • Progression-Free Survival improved with MRD-guided ibrutinib and venetoclax in CLL patients, especially those with TP53 mutations.
  • 5-year PFS was 100% for TP53mut patients on MRD-guided therapy, contrasted with 70% for ibrutinib and 62.3% for FCR.
  • Analysis employed Fluorescent In Situ Hybridization and sequenced DNA from patients to identify chromosomal abnormalities and mutations.
  • Chemoimmunotherapy remains significant in treating patients with CLL, especially those facing challenges from recurrent genetic aberrations.

Cite This Study

Shingles et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8d1https://doi.org/10.1182/blood-2025-679
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FCR-I/iven combination for CLL: «Cheap but fierce»2025
  2. 2Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY2025
  3. 3Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients2025 · 3 citations
  4. 4Cladribine, idarubicin, and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A pooled analysis of prospective trials2025
  5. 5A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial2025